Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-PATH trial of dual versus single antiplatelet therapy after endovascular revascularization for peripheral artery disease
NL-OMON60440Phase 4Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin and clopidogrel in arteriosclerosis obliterans (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary composite endpoint at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
aspirinclopidogrel
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON60440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60440.